Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iSCLife X-Arouse+ is a stem cell-based anti-aging and regenerative therapy developed by Sclnow Biotechnology. The product is formulated with umbilical cord mesenchymal stem cells (UC-MSCs) as the primary active ingredient, supplemented with cell growth factors, epidermal growth factor, fibrin glue, and other stem cell activating factors. It is designed to activate dormant stem cell populations throughout the body to replace degenerated or aging tissue cells, thereby restoring organ and tissue function. The therapy works through the regenerative and paracrine properties of mesenchymal stem cells, which promote immunomodulation, enhance micro-circulation, and facilitate cellular communication. It is intended for applications in anti-aging, immune regulation, and disease rehabilitation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iSCLife X-Arouse+.